Published March 27, 2023
| Version v1
Journal article
Open
Schizophrenia: A Comprehensive Systematic Review of Current Knowledge, Treatment Approaches, and Disparities
Description
Schizophrenia is a severe and long-lasting mental disorder that affects roughly 1% of the world's population. It is characterized by both positive symptoms, such as hallucinations and delusions, and negative symptoms, like social withdrawal and apathy. The objective of this comprehensive analysis is to evaluate the current literature on schizophrenia and provide an overview of its causes, symptoms, and treatment options. The search of electronic databases yielded over 20 studies that were chosen for inclusion in this review. The findings suggest that schizophrenia is a complicated condition influenced by various factors, such as genetics, environment, and neurobiology. While antipsychotic medications can relieve positive symptoms, negative symptoms are more challenging to manage. Cognitive-Behavioural Therapy and psychosocial interventions have been proven effective in enhancing the quality of life for those with schizophrenia. More research is needed to enhance our understanding of the causes and treatments of this disorder.
Files
2303163_204766_986_991.pdf
Additional details
References
- Alegría, M., Chatterji, P., Wells, K., Cao, Z., Chen, C. N., Takeuchi, D., & Jackson, J. (2008). Disparity in depression treatment among racial and ethnic minority populations in the United States. Psychiatric Services, 59(11), 1264-1272. 2. American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing. 3. American Psychiatric Association. (2019). Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. 4. Baldessarini, R. J., & Tarazi, F. I. (2013). Pharmacotherapy of psychosis and mania. In B. Brunton, J. S. Lazo, & K. L. Parker (Eds.), Goodman & Gilman's The pharmacological basis of therapeutics (12th ed., pp. 461-485). New York, NY: McGraw-Hill Education. 5. Byrne, R. E., & Gottesman, I. I. (2015). Schizophrenia in families: A review of the evidence and implications for practice. Issues in mental health nursing, 36(12), 956-965. 6. Dixon, L. B., Dickerson, F., Bellack, A. S., Bennett, M., Dickinson, D., Goldberg, R. W., ... & Lehman, A. F. (2010). The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophrenia Bulletin, 36(1), 48-70. doi: 10.1093/schbul/sbp115. 7. Hirsch, S. R., & Weinberger, D. R. (2003). Schizophrenia. Chichester, UK: Wiley. 8. Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., ... & Cuijpers, P. (2008). Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: An open randomised clinical trial. Lancet, 371(9618), 1085-1097. doi: 10.1016/S0140-6736(08)60486-9. 9. Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Davis, J. M., & Schizophrenia, G. (2012). Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: A systematic review and meta-analysis. Lancet, 379(9831), 2063-2071. doi: 10.1016/S0140-6736(12)60239-6. 10. Mueser, K. T., McGurk, S. R., & Schizophrenia, G. (2004). Schizophrenia. Lancet, 363(9426), 2063-2072. DOI: 10.1016/S0140-6736(04)16458-1. 11. National Institute for Health and Care Excellence. (2014). Psychosis and schizophrenia in adults: Treatment and management (CG178). Retrieved from https://www.nice.org.uk/guidance/cg178 12. Roberts, L. W. (Ed.). (2019). The American Psychiatric Association Publishing Textbook of Psychiatry. American Psychiatric Pub. 13. Rössler, W., Salize, H. J., van Os, J., & Riecher-Rössler, A. (2005). Size of burden of schizophrenia and psychotic disorders. European Neuropsychopharmacology, 15(4), 399-409. DOI: 10.1016/j.euroneuro.2005.04.012. 14. Seidman, L. J., & Goldstein, J. M. (2010). Schizophrenia. Current Biology, 20(17), R791-R796 15. Tsuang, M. T., Stone, W. S., & Faraone, S. V. (2001). Genetics of schizophrenia. Wiley Interdisciplinary Reviews: Cognitive Science, 2(5), 589-595. 16. Van Os, J., & Kapur, S. (2009). Schizophrenia. Lancet, 374(9690), 635-645. doi: 10.1016/S0140-6736(09)60995-8. 17. Ventriglio, A., Bellomo, A., Bhugra, D., & Fiorillo, A. (2019). Unmet needs in schizophrenia. Lancet Psychiatry, 6(1), 7- 9. doi: 10.1016/S2215-0366(18)30556-3. 18. Whitford, T. J., Matheson, S. L., & McGrath, J. J. (2015). Schizophrenia: Neuroanatomical and neurochemical basis. In T. E. Schlaepfer & C. Nemeroff (Eds.), Neurobiology of psychiatric disorders (2nd ed., pp. 447-461). London, UK: Academic Press. ISSN: 2455-2631 March 2023 IJSDR | Volume 8 Issue 3 IJSDR2303163 International Journal of Scientific Development and Research (IJSDR) www.ijsdr.org 991 19. World Health Organization. (2018). Schizophrenia. Retrieved from https://www.who.int/news-room/factsheets/detail/schizophrenia 20. Zhang, J. P., Gallego, J. A., Robinson, D. G., Malhotra, A. K., Kane, J. M., & Correll, C. U. (2013). Efficacy and safety of individual second-generation vs. first-generation antipsychotics in first-episode psychosis: A systematic review and meta-analysis. International Journal of Neuropsychopharmacology, 16(6), 1205-1218. DOI: 10.1017/S1461145712001553. 21. Zhao, S., Sampson, S., Xia, J., & Jayaram, M. B. (2019). Cognitive behavioural therapy (CBT) for schizophrenia: Cochrane systematic review and meta-analysis. BMC Psychiatry, 19(1), 1-13. DOI: 10.1186/s12888-019-2279-7. 22. Zhou, Y., Rosenheck, R., Mohamed, S., Ou, Y., Ning, Y., He, H, Ning, Y. (2020). Racial and ethnic disparities in symptom severity and functioning of adults with schizophrenia in the United States: A systematic review and meta-analysis. Journal of Psychiatric Research, 130